Person:
ÇOBAN, EYÜP

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ÇOBAN

First Name

EYÜP

Name

Filters

20232
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Retrospective comparison of the efficacy of therapeutic agents in metastatic soft-tissue sarcomas
    (Kare Yayınevi, 2023-03-02) Caner, Burcu; Ocak, Birol; Şahin, Ahmet Bilgehan; Salı, Seda; Çoban, Eyüp; Deligönul, Adem; Çubukçu, Erdem; Evrensel, Türkkan; CANER, BURCU; SALİ, SEDA; ÇOBAN, EYÜP; DELİGÖNÜL, ADEM; ÇUBUKÇU, ERDEM; EVRENSEL, TÜRKKAN; Tıp Fakültesi; Tıbbi Onkoloji Ana Bilim Dalı; 0000-0003-1591-3323 ; HJH-6371-2023; DPO-3759-2022; JIS-1916-2023; JHC-1731-2023; JGT-4101-2023; EXZ-0745-2022
    OBJECTIVEThere are few agents used in soft-tissue sarcoma treatment. We compared the efficacy of therapies, aiming to identify the best therapy sequence, and reveal the factors affecting the risk of progression or death.METHODSFifty-five patients were included in the study. Data such as age, gender, tumor primary site, histological type, tumor grade, the Ki67 percentage score, treatments, radiotherapy, and metastasectomy history, the dates of diagnosis, metastasis, progression, and death were retrospectively evaluated. Progression-free survival (PFS) and overall survival (OS) for therapies, and the risk factors for the progression or death were analyzed.RESULTSIn the first-line, gemcitabine-docetaxel provided longer PFS than the doxorubicin-ifosfamide combination (7.4 months vs. 4.8 months, p=0.035), although this did not result in OS difference. In the second line, the efficacy of trabectedin and pazopanib were similar, whereas trabectedin showed less activity in liposarcomas. In the third-line and beyond, trabectedin, pazopanib and eribulin showed similar PFS and OS. The only factor that affected the risk of death was metastasectomy (HR for death: 0.35, 95% CI: 0.18-0.66, p=0.001). CONCLUSIONWe found that agents used in soft-tissue sarcoma have similar efficacy, which is not affected by the previous therapies. However, it should be noted that soft-tissue sarcomas include many histological types, and to choose the optimal drug, the histological type must be one of the major factors considered. Furthermore, all patients should be evaluated for possible metastasectomy, which came out as the only factor reducing the risk of death in our study.
  • Thumbnail Image
    Publication
    Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: Data from the Turkish oncology group
    (Oxford Univ Press, 2023-09-07) Ünal, Çaglar; Azizy, Abdulmünir; Karabulut, Senem; Taştekin, Didem; Akyıldız, Arif; Yaşar, Serkan; Yalçın, Şuayib; Çoban, Eyup; Evrensel, Türkkan; Kalkan, Ziya; Oruç, Zeynep; Derin, Sumeyra; Turna, Zeynep Hande; Bayram, Dogan; Kos, Fahriye Tugba; Şendur, Mehmet Ali Nihat; Sever, Nadiye; Ercelep, Öezlem; Seyyar, Mustafa; Kefeli, Umut; Uygun, Kazim; Özcelik, Melike; Ön, Sercan; Şanli, Ulus Ali; Canaslan, Kubra; Unek, İlkay Tuba; Yucel, Kadriye Bir; Özdemir, Nuriye; Yazici, Ozan; Guzel, Halil Goksel; Salim, Derya Kivrak; Goksu, Sema Sezgin; Tatli, Ali Murat; Ordu, Çetin; Selvi, Oguzhan; Şakin, Abdullah; Buyukbayram, Mehmet Emin; Dursun, Bengu; Ürun, Yuksel; Arak, Haci; Agdas, Gozde; Ugrakli, Muzaffer; Hendem, Engin; Eryilmaz, Melek Karakurt; Bilgin, Burak; Topcu, Atakan; Şimsek, Melih; Buyuksimsek, Mahmut; Akay, Busra; Erdal, Gülçin Şahingöz; Karatas, Fatih; Alan, Özkan; Çaglayan, Melek; Kahvecioglu, Fatma Akdag; Demirci, Ayse; Paksoy, Nail; Çetin, Bulent; Gümüş, Mahmut; Ak, Naziye; Aydinalp, Yasemin; Paydaş, Semra; Guven, Deniz Can; Kılıçkap, Saadettin; Sağlam, Sezer; ÇOBAN, EYÜP; EVRENSEL, TÜRKKAN; Tıp Fakültesi; Dahiliye Ana Bilim Dalı; Tıbbi Onkoloji Bilim Dalı; EUT-7725-2022; EXZ-0745-2022
    Introduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).Methods: We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey.Results: The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second-and =third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment.Conclusions and Relevance: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.